乳腺癌患者新辅助化疗前后HER-2表达的变化

目的研究新辅助化疗后乳腺癌患者HER-2表达的变化，为乳腺癌的个体化治疗提供依据。方法137例乳腺癌在粗针穿刺或麦默通活检，行荧光原位杂交法(FISH)检测HER-2状态。所有病例术前均进行2~6周期的FEC、TE或AC方案新辅助化疗，术后再次检测HER-2状态。结果137例术前病人中，FISH检测HER-2阳性22例，化疗后有8例化疗达病理学完成缓解（HER-2阳性3例，阴性5例），部分缓解91例，稳定24例，无效14例。术后FISH检测22例阳性（8例病理学完全缓解患者未做检测）,新辅助化疗前阳性患者化疗后仍表达阳性。阴性者有3例转化为阳性,化疗前后变化无统计学差异（P>0.05）。结论新辅助化疗对HER-2阳性表达者没有影响，而阴性表达者可转换为阳性，但差异无统计学意义。

Alteration of Biomarker HER-2 between Pre-and Post-neoadjuvant Chemotherapy in Breast Cancer Patients

Objective To study the HER-2 expression after the breast cancer neoadjuvant chemotherapy.Methods HER-2 was detected by fluorescence in situ hybridization(FISH) methods after core needle or Mammotome biopsy in 137 cases.Two~Six cycles neoadjuvant chemotherapy(including FEC,TE and AC regimens) later,HER-2 was detected again.Results HER-2 of 22 cases was positive,and 115 cases were negative.8 cases(including 3 HER-2 positive and 5 HER-2 negative cases) were complete response(CR),91 cases were partial response(...